Lanadelumab Completed Phase 3 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04590586Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients